Impax Laboratories, Inc.: Impax and Amneal's All-Stock Merger Is Credit Positive
CORPORATES ISSUER COMMENT 23 October 2017 Contacts Morris Borenstein +1.212.553.1409 AVP-Analyst [email protected] Impax Laboratories, Inc. Impax and Amneal’s All-Stock Merger Is Credit Positive From Credit Outlook Last Tuesday, generic drug manufacturers Impax Laboratories Inc.  (B2 review for upgrade) and Amneal Pharmaceuticals, LLC  (B1 stable) announced pAmneal Pharmaceuticals is a pharmaceutical company, engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products, as well as branded products. Co. operates in two segments: Impax Generics, which develops, manufactures, sells and distributes solid dose and alternative dosage form products covering a range of therapeutic areas, and generic pharmaceuticals; and Impax Specialty Pharma, which is engaged in the development, sale and distribution of branded pharmaceutical products addressing central nervous system disorders, including migraine, multiple sclerosis, Parkinson's disease and post-herpetic neuralgia, and other select specialty segments.
Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:
- 130 countries
11,000 corporate issuers
21,000 public finance issuers
76,000 structured finance obligations
Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.
Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.